Literature DB >> 14617304

Severe recurrent cytomegalovirus disease revealed by a colocutaneous fistula in a kidney transplant recipient.

A Dumoulin1, H Boulmerka, J Tran Van Nhieu, P Lang, C Baron.   

Abstract

Intestinal disorders are classical complications of cytomegalovirus (CMV) infection in kidney transplant recipients (Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002: 13: 277-287). Severe ulcerative colitis that is sometimes lethal has been reported (Foucar E, Mukai K, Foucar K, Sutherland DE, Van Buren CT. Colon ulceration in lethal cytomegalovirus infection. Am J Clin Pathol 1981: 76: 788-801 and Frankel AH, Barker F, Williams G, Benjamin IS, Lechler R, Rees AJ. Neutropenic enterocolitis in a renal transplant patient. Transplantation 1991: 52: 913-914). The immunosuppressive drugs currently used, and notably mycophenolate mofetil (Cellcept), cause significant changes in the incidence, duration, and viral load of CMV infections with severe atypical forms of CMV disease (De Maar EF, Verschuuren EA, Homan vd Heide JJ, et al. Effects of changing immunosuppressive regimen on the incidence, duration and viral load of cytomegalovirus infection in renal transplantation: a single center report. Transpl Infect Dis 2002: 4: 17-24 and Perez Valentin MA, Cofan F, Sole M, et al. Atypical cytomegalovirus in renal transplantation: a new form of presentation. Nefrologia 2002: 22: 381-385). This report describes a patient who suffered from several episodes of colitis due to an unusual and late-appearing CMV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617304     DOI: 10.1034/j.1399-3062.2003.00014.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  1 in total

1.  Enterocolic fistula: A rare presentation of cytomegalovirus infection.

Authors:  Richdeep S Gill; Geoffrey Taylor; Robert M Penner; Sarvesh Logsetty
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.